PCSK9 and dentatorubral-pallidoluysian atrophy: Since new-onset diabetes (NOD) with statins was evident many years after regulatory approval through meta-analyses of multiple trials [17], the present review will address the evidence pertaining to the risk of NOD associated with PCSK9 inhibition.